Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
This piece highlights why new investors favor index funds, emphasizing simplicity, cost efficiency, and dependable long-term results.
21,776 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Home listings are cooling fast as sellers reset prices. The latest data show a record decline in home asking prices, ...
As a new Federal Reserve chair makes his debut, Jim Cramer argues markets should expect stability, not shocks. Trader...
Palantir Technologies and NVIDIA expanded their collaboration to accelerate government-grade AI models, sending Palan...
ADA rebounded about 40% from a late-June trough, with Cardano showing signs life as investors digest a major upgrade ...
Higharc AI has closed a $95 million Series C, backed by USLBM, to accelerate AI-enabled homebuilding. The move aims t...
Markets await the Federal Reserve's June minutes to gauge the central bank's policy path under the rumored new chair....
Markets swing after headlines suggest a faltering Iran ceasefire, reigniting energy risk and shifting bets on Fed pol...
As rates shift and inflation cools, retirees seek a retirement portfolio that pays steady income with less daily tink...
Leveraged ETFs have surged toward $200 billion in assets under management, raising questions about how daily rebalanc...
A newlywed couple with a sizable debt and a landlord’s portfolio faces a blunt financial question on The Ramsey Show:...
Apple filed a federal lawsuit alleging trade secret theft by former employees at OpenAI, threatening hardware know-ho...